Two new studies from Sanofi and GSK add to promising signs that Covid-19 variant vaccines can broaden immune response
If you’ve had Covid before, why can you get it again? WSJ’s Daniela Hernandez explains what the possibility of reinfections means for the future of public-health policy and the Covid-19 pandemic.
Illustration: David FangA Covid-19 vaccine developed by Sanofi SA and GSK PLC to target the Beta strain of the virus produced a stronger antibody response against variants of Omicron when given as a booster compared with certain first-generation shots, two studies have found.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Ringo Starr Postpones Summer Tour Dates After All Starr Band Members Test Positive for COVID-19“We are so sorry to let the fans down,” the legendary Beatles drummer said.
Lire la suite »
Sleeping issues linked to long-haul COVID-19Medical research points to sleeping issues as one of the long term effects of COVID-19. A doctor explains why.
Lire la suite »
Research behind COVID-19 vaccines reaps close to $1 billion in royalties for PennPenn officials said they are plowing the money back into early-stage scientific research.
Lire la suite »
Cross Country Memorial Honors Haltom City Officer Who Died of COVID-19A nationwide effort to remember fallen members of law enforcement arrived in Haltom City to honor one of its own.
Lire la suite »
US: Pfizer COVID-19 shot appears effective for kids under 5WASHINGTON (AP) — Federal health officials said Sunday that kid-sized doses of Pfizer’s COVID-19 vaccines appear to be safe and effective for kids under 5, a key step toward a long-awaited decision to begin vaccinating the youngest American children .
Lire la suite »
US: Pfizer COVID-19 shot appears effective for kids under 5Federal health officials said Sunday that kid-sized doses of Pfizer’s COVID-19 vaccines appear to be safe and effective for kids under 5, a key step toward a long-awaited decision to begin vaccinating the youngest American children.
Lire la suite »